 Connection
Christopher Domen to Parkinson Disease
This is a "connection" page, showing publications Christopher Domen has written about Parkinson Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.686 |
|
|
|
-
Domen CH, Sillau S, Liu Y, Leehey MA. Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds. Mov Disord. 2024 Jan; 39(1):222-223.
Score: 0.581
-
Domen CH, Sillau S, Liu Y, Adkins M, Rajkovic S, Bainbridge J, Sempio C, Klawitter J, Leehey MA. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and ?9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms. Mov Disord. 2023 07; 38(7):1341-1346.
Score: 0.557
-
Wodushek TR, Domen CH. Comparing two models of performance validity assessment in patients with Parkinson's disease who are candidates for deep brain stimulation surgery. Appl Neuropsychol Adult. 2020 Jan-Feb; 27(1):9-21.
Score: 0.402
-
Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, Thompson JA, Seawalt T, Klawitter J, Sempio C, Chin G, Forman L, Fullard M, Hawkins T, Seeberger L, Newman H, Vu D, Leehey MA. Short-Term Cannabidiol with ?-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Mov Disord. 2024 May; 39(5):863-875.
Score: 0.147
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|